Optimal Subcutaneous Lecanemab Dose Found in Modeling Study

The optimal dose of under-the-skin (subcutaneous) lecanemab, Eisai’s experimental therapy for early Alzheimer’s disease, has been determined in a modeling study. The dose is currently being evaluated in the Phase 3 Clarity AD open-label extension study (NCT03887455). “Eisai’s broad clinical program for lecanemab continues to deliver data…

Older Adults Aware of Alzheimer’s, But Know Little About Aduhelm

Although the vast majority of older Americans are concerned about Alzheimer’s disease, most are unaware of Aduhelm (aducanumab), the recently approved treatment for the disease, according to a survey study. “The contrast between older Americans who were very concerned about developing Alzheimer’s disease and those that actually knew…

FDA Approves Aduhelm, First Targeted Alzheimer’s Therapy

For the first time in almost 18 years, the U.S. Food and Drug Administration (FDA) has approved a new treatment — Aduhelm, also known as aducanumab — for Alzheimer’s disease, and a first targeted treatment for patients. With this approval, Aduhelm becomes the first disease-modifying therapy for Alzheimer’s, and…